IBT_B: IBP-9414's Phase 3 trial showed 27% lower mortality; BLA submission planned for 2025

About this update from Infant Bacterial Therapeutics Ab Class B

IBT completed its pivotal Phase 3 trial for IBP-9414, showing a 27% reduction in mortality among preterm infants, and is preparing a BLA for FDA submission in 2025. Financials reflect a net loss of SEK 136.9 million, with sufficient liquidity for upcoming regulatory milestones.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Infant Bacterial Therapeutics Ab Class B